Adoptive T-cell therapy for cancer: The era of engineered T cells
Eur J Immunol, 45 (9):
2457-2469 (September 2015)this article by the Bonini who is presenting her work to an international conference of the AAAS ongoing in these days Feb 17 2016.DOI: 10.1002/eji.201545552
Abstract
Tumors originate from a number of genetic events that deregulate homeostatic mechanisms controlling normal cell behavior. The immune system, devoted to patrol the organism against pathogenic events, can identify transformed cells, and in several cases cause their elimination. It is however clear that several mechanisms encompassing both central and peripheral tolerance limit antitumor immunity, often resulting into progressive diseases. Adoptive T-cell therapy with either allogeneic or autologous T cells can transfer therapeutic immunity. To date, genetic engineering of T cells appears to be a powerful tool for shaping tumor immunity. In this review, we discuss the most recent achievements in the areas of suicide gene therapy, and TCR-modified T cells and chimeric antigen receptor gene-modified T cells. We provide an overview of current strategies aimed at improving the safety and efficacy of these approaches, with an outlook on prospective developments.
Description
Adoptive T-cell therapy for cancer: The era of engineered T cells. - PubMed - NCBI